Semaglutide
FDA ApprovedA GLP-1 receptor agonist FDA-approved for type 2 diabetes, obesity, cardiovascular risk reduction, and MASH. Among the most extensively studied peptides with robust Phase 3 data demonstrating significant metabolic, cardiovascular, renal, and hepatic benefits.
Ozempic · Wegovy · Rybelsus · NN9535
78 human studies
- Preclinical
- 18%
- Clinical
- 82%
Based on 95 cited sources
clinically demonstrated · high confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 100: meta-analyses of multiple large low-RoB Phase 3 RCTs (SUSTAIN 27633186, STEP 33567185, SELECT 37952131 N=17,604) with total human N far exceeding 1,000 and direct population/route/outcome match. Mechanism 100: GLP-1R binding plus functional and knockout/antagonist confirmation, full target-to-effect pathway, in-vivo dose-response (STEP UP 40961952). Plausibility 98: full mechanism->surrogate->clinical chain proven across metabolic, CV (37952131/40162642), renal (38785209) and hepatic (40305708) outcomes, with class analogues; minor deduction for multi-system breadth. Global Coverage 100: reproduced across many independent groups/40+ countries, >100 studies, multi-regulator approval. Community Experience 92: large multi-year population-level use, highly consistent reports, but recurring GI and a documented AKI signal cap 5D. Effectiveness basis clinical (high): STEP 1 14.9% vs 2.4% placebo, far exceeds the ~5% MCID, hard patient-relevant outcomes, top-tier vs active comparators though edged head-to-head by tirzepatide.
Semaglutide is a selective GLP-1 receptor agonist with extensive Phase 3 clinical trial data supporting its mechanisms in humans.
How It Works (Simplified)
Semaglutide mimics GLP-1, a natural hormone released after eating, producing multiple therapeutic effects:
Binds to GLP-1 receptors on pancreatic beta cells, triggering glucose-dependent insulin release. Only works when blood sugar is elevated, minimizing hypoglycemia risk.
Acts on hypothalamic hunger centers, activating satiety pathways (POMC/CART) while suppressing hunger signals (NPY/AgRP). Reduces caloric intake by 20-35%.
Suppresses inappropriate glucagon secretion from alpha cells and enhances insulin sensitivity, improving overall glycemic control in type 2 diabetes.
Slows stomach emptying, prolonging satiety after meals and reducing postprandial glucose spikes. Contributes to both weight loss and glycemic benefits.
Key Research: SUSTAIN and STEP Phase 3 programs demonstrated these mechanisms translate to clinically meaningful outcomes in over 20,000 patients. PMID:33567185
2025-2026 Developments
Oral Wegovy Approval: The FDA approved oral semaglutide 25mg (Wegovy) in December 2025, marking the first oral GLP-1 formulation approved for chronic weight management at a launch price of approximately $149/month.
MASH Indication: Semaglutide received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), expanding its therapeutic indications beyond diabetes and obesity.
Safety Signal — Acute Kidney Injury: A 2025 disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) found that semaglutide carried a reporting signal for acute kidney injury, typically attributed to dehydration from GI adverse events; the authors recommend ensuring hydration and renal monitoring when initiating therapy (PMID: 41227073).
Patent Landscape: The core semaglutide compound patent expired in March 2026 across several major markets including India, Canada, China, Brazil, and Turkey, with 40+ biosimilar applications filed in India alone.
Important Limitations
- Common GI side effects: Nausea (30-45%), vomiting, diarrhea, and constipation, especially during dose titration
- Boxed warning: Thyroid C-cell tumors observed in rodents; contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2
- Gallbladder disease: Increased risk (~2.5%) associated with rapid weight loss
- Pancreatitis: Rare (~0.3%) but requires discontinuation if suspected
- Pregnancy: Contraindicated; discontinue at least 2 months before planned conception
- Weight regain: Approximately 2/3 of lost weight returns within 1 year of discontinuation (STEP 4)
- Muscle mass: ~30% of weight lost is lean mass; resistance training recommended
Reported positives
- Significant appetite suppression reported within first week
- Reduced food noise and cravings consistently cited
- Improved relationship with food and reduced binge eating
- Cardiovascular improvements noted by users with comorbidities
Reported negatives
- Nausea and GI distress common during dose escalation
- Muscle loss reported without resistance training
- Fatigue and low energy during initial weeks
- Hair thinning reported by some users during rapid weight loss
“Most discussed peptide online. r/semaglutide has 200K+ members. Extensive patient community feedback.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
| NCT ID | Title | Peptide | Phase | Status | Completion |
|---|---|---|---|---|---|
| NCT02128932 | SUSTAIN-6: Cardiovascular Outcomes Trial | Semaglutide | Phase 3 | Completed | Jan 2016 |
| NCT03548935 | STEP 1: Weight Management in Obesity | Semaglutide | Phase 3 | Completed | Jan 2020 |
| NCT03552757 | SELECT: CV Outcomes in Obesity without Diabetes | Semaglutide | Phase 3 | Completed | Jan 2023 |
| NCT04777396 | FLOW: Kidney Outcomes in T2D with CKD | Semaglutide | Phase 3 | Completed | Jan 2024 |
| NCT04777409 | EVOKE: Semaglutide in Early Alzheimer's Disease | Semaglutide | Phase 3 | Recruiting | - |
| NCT06977438 | Promoting Healthy Children and Youth Obesity, Childhood | Semaglutide | Phase 4 | Not yet recruiting | Jan 2031 |
| NCT07027969 | Metabolic Surgery for Atrial Fibrillation Elimination Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Semaglutide | Phase 4 | Not yet recruiting | Dec 2029 |
| NCT07389941 | Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation Atrial Fibrillation (AF) | Semaglutide | Phase 4 | Not yet recruiting | Apr 2029 |
| NCT07462663 | SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer (Phase 1) Endometrial Cancer, Endometrial Cancer Stage I +7 more | Semaglutide | Phase 4 | Not yet recruiting | May 2027 |
| NCT07282613 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes Diabetes Mellitus, Type 2 | Semaglutide | Phase 3 | Not yet recruiting | Sep 2029 |
| NCT07357766 | A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight Overweight, Obesity | Semaglutide | Phase 3 | Not yet recruiting | Nov 2027 |
| NCT06934655 | Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth Pediatric Obesity, Metabolic and Bariatric Surgery +1 more | Semaglutide | Phase 3 | Not yet recruiting | Nov 2030 |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight Obesity, Type 2 Diabetes | Semaglutide | Phase 3 | Recruiting | Feb 2028 |
| NCT07021937 | Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity Obesity/Therapy | Semaglutide | Phase 3 | Not yet recruiting | Apr 2031 |
| NCT07554417 | Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 GLP - 1, Obesity & Overweight +3 more | Semaglutide | Phase 4 | Not yet recruiting | Jun 2026 |
| NCT06975111 | Focusing on the Menopausal Transition to Improve Mid-Life Women's Health Menopause, Menopause Hot Flashes +2 more | Semaglutide | Phase 2/3 | Recruiting | Oct 2029 |
| NCT07059377 | Semaglutide for Smoking Cessation in Patients With Diabetes Diabetes Mellitus, Type 2, Nicotine Addiction +1 more | Semaglutide | Phase 3 | Recruiting | Jul 2026 |
SELECT: CV Outcomes in Obesity without Diabetes
Promoting Healthy Children and Youth
Metabolic Surgery for Atrial Fibrillation Elimination
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer (Phase 1)
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Semaglutide for Smoking Cessation in Patients With Diabetes
Initial titration period. Studies show GI side effects (nausea 30-45%) are most common during dose escalation. Early appetite reduction begins. HbA1c improvements start becoming measurable. Weight loss typically 2-4% by week 4.
PMID:33567185Continued dose escalation toward maintenance dose. GI tolerability typically improves as body adapts. Weight loss accelerates to 5-8%. Blood glucose improvements become more pronounced.
PMID:33567185Approaching full therapeutic effect. STEP 1 showed approximately 10-12% weight loss by week 20. HbA1c reductions of 1.0-1.5% typical in diabetes trials. Blood pressure begins to improve.
PMID:33567185Near-maximum weight loss achieved. STEP 1 showed 14.9% mean weight loss at 68 weeks. Cardiovascular markers improve. MASH patients show liver enzyme improvements.
PMID:33567185Weight loss typically plateaus and is maintained with continued use. STEP 5 showed maintenance at 2 years. Discontinuation results in weight regain (~2/3 of lost weight within 1 year per STEP 4).
PMID:33755728Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Tesamorelin
CautionBoth affect metabolic parameters. Tesamorelin increases GH which may affect glucose homeostasis. Monitor blood glucose closely if considering combination in diabetic patients.
BPC-157
CautionBoth affect GI function. BPC-157 is gastroprotective while semaglutide delays gastric emptying. Theoretical interaction unclear; monitor GI symptoms.
Ipamorelin
CautionGH secretagogues may affect glucose metabolism. Semaglutide treats diabetes while GH can be diabetogenic. Monitor glucose parameters if combined.
MK-677
CautionMK-677 increases GH and IGF-1, which can impair glucose tolerance. May counteract semaglutide's glycemic benefits. Monitor blood glucose closely.
Tirzepatide
AvoidDo not combine. Both are incretin-based therapies acting on overlapping pathways. Concurrent use would provide redundant GLP-1 agonism with increased risk of severe GI adverse events and hypoglycemia without proven additional benefit.
Liraglutide
AvoidDo not combine. Both are GLP-1 receptor agonists with identical mechanism of action. No clinical rationale for combination; would increase adverse event risk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Semaglutide
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Related Content
Tirzepatide
Metabolic · high evidence
Liraglutide
Metabolic · high evidence
What is Ozempic?
An introduction to Ozempic, the brand name for semaglutide a...
What is Rybelsus?
An introduction to Rybelsus, the oral tablet form of semaglu...
5-Amino-1MQ vs Semaglutide
View side-by-side analysis
Amycretin vs Semaglutide
View side-by-side analysis